Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

NCT02689427 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02689427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2016
Completion date
November 15, 2023
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast carcinoma, stage i breast cancer ajcc v7, stage ia breast cancer ajcc v7, stage ib breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, triple-negative breast carcinoma